Phaseline

Companies › Neurimmune

Neurimmune: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Cardiovascular.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALXN2220
anti-transthyretin (TTR) monoclonal antibody
TTRPhase 2Amyloid Transthyretin Cardiomyopathy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07213583ALXN2220Phase 2Amyloid Transthyretin CardiomyopathyCardiovascularOct 2026

Targets

TTR (1)

Companies with the same targets

Alnylam Pharmaceuticals AstraZeneca Novo Nordisk Intellia Therapeutics Eidos Therapeutics, a BridgeBio company Ionis Pharmaceuticals Qilu Pharmaceutical

Companies built like this

Eidos Therapeutics, a BridgeBio company Tectonic Operating Company CuraSen Therapeutics Seismic Pharmaceuticals Operations Foresee Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.